Background: The number of ruptured abdominal aortic aneurysm (r-AAA) patients who are treated by endovascular means is increasing as ruptured endovascular aneurysm repair (r-EVAR) enters the mainstream. However, even today, data on the incidence and behavior of endoleaks after r-EVAR are scarce. This study analyzed whether endoleaks behave differently after EVAR for rupture vs elective AAA repair.
Elective endovascular aneurysm repair (e-EVAR) has witnessed substantial improvements in technology and techniques during the past two decades insomuch that today, even ruptured abdominal aortic aneurysms (r-AAAs) routinely undergo ruptured endovascular aneurysm repair (r-EVAR). [1] [2] [3] [4] Currently, r-EVAR has evolved far beyond simply being feasible. Many studies have shown r-EVAR to be associated with improved efficacy in managing r-AAA compared with open surgical repair (OSR). [5] [6] [7] [8] [9] [10] Furthermore, although the literature has fully characterized e-EVAR and its benefits over elective OSR, 11, 12 we have only recently begun to explain differences between EVAR and OSR in patients with r-AAA.
As the practice of r-EVAR continues to evolve, we recognize that the two EVAR procedures for elective repair and r-AAA differ in our approach, protocols, and outcomes. 13, 14 There is an increasing need for data on outcomes including complications, endoleaks, and secondary interventions. We have learned much about the incidence and behavior of endoleaks after e-EVAR, which can occur in 10% to 40% of patients. [15] [16] [17] [18] [19] However, our knowledge of the incidence, behavior, and significance of endoleaks after r-EVAR is evolving, and much work is needed in further characterizing not only the fate of these endoleaks but also the need for secondary interventions. This study sought to analyze the differences in endoleaks and outcomes in comparing e-EVAR and r-EVAR.
METHODS
From January 5, 2002 , to June 19, 2013 , there were 2052 patients who underwent EVAR for treatment of rupture (n ¼ 166 [8.1%] ) and elective repair (n ¼ 1886 [91.9%]) of infrarenal AAAs. Data on these patients undergoing EVAR for either r-AAA or an elective repair were prospectively collected in a vascular registry for retrospective review. The experimental protocol used within this study was approved by the Institutional Review Board. As this was a retrospective review, informed consent was not obtained at the time of data collection. Information about patient demographics, comorbidities, intraoperative complications, and postoperative mortality and morbidity as well as stent grafts used and revisions made postoperatively was collected. A retrospective analysis was used to compare the complication and revision rate in those undergoing repair of r-AAA compared with those undergoing an elective repair. Dichotomized variables that could affect outcome include sex, diabetes, and smoking and the presence of coronary artery disease, hypertension, pulmonary embolism, hyperlipidemia, renal disease, abdominal compartment syndrome, and multisystem organ failure. Additional nominal variables are the type of procedure performed and stent grafts used. Continuous variables that could affect outcome are blood loss and partial thromboplastin time as a measure of coagulopathy. U.S. Food and Drug Administrationapproved and commercially available stent grafts were used for all the procedures; the specific stent graft type was determined by the patients' aortoiliac morphology and the surgeons' preference. Modular bifurcated devices were placed in all patients. Patients with snorkel, chimney, sandwich, and periscope reconstructions were excluded from analysis. Late mortality data were obtained through multiple sources.
The method by which an r-AAA patient is treated with EVAR has been described earlier. 13 All patients in both r-EVAR and e-EVAR groups had preoperative computed tomography scans to determine feasibility and the endograft dimensions necessary for the endovascular procedure. When our group first initiated the r-EVAR protocol, one vascular surgeon performed most of the procedures. However, during the last 5 years, many of the vascular surgeons in the group have become confident with the use of EVAR under emergency circumstances and have thus adopted the technique. When abdominal compartment syndrome developed in the acute postoperative period, midline laparotomy was performed as a decompressive procedure with no attempt to explore the hematoma. Repeated exploratory laparotomy was performed as necessary to preferentially manage and facilitate closure of the midline wound. In addition, all patients in the r-EVAR group underwent routine colonoscopy on the first postoperative day to rule out colonic ischemia. Those patients with grade 3-4 ischemia or signs of sepsis or hemodynamic collapse associated with any grade of ischemia underwent exploratory laparotomy. 20 Postoperative follow-up for these patients included clinical examination, duplex ultrasound imaging, and computed tomography angiography at 1 month, 6 months, and 12 months as well as yearly thereafter. All patients undergoing r-EVAR had completion arteriography performed before completion of the procedure, and no patient in this group left the operating suite with a known type I or type III endoleak. As noted before, the first postoperative computed tomography scan was performed at 1 month after the procedure unless there was a clinical indication to perform imaging earlier. Persistent type II endoleaks at >6 months after EVAR without a decrease in AAA sac underwent translumbar or transfemoral embolization procedures. On occasion after the operation and after hospital discharge, the stent grafts would fail and an explantation would be necessary. Before endograft explantation was performed, all endovascular means to repair endoleaks including proximal and distal graft extension, coil embolization, and secondary EVAR were performed. Grafts were explanted for continued AAA sac growth, symptoms of pain, or sac rupture. 21 Statistical analysis. Several tests were used to assess the association of potential predictor variables. Yates corrected c 2 test of association was used to test for associations between two nominal variables. If a predicted cell frequency was <5, Fisher exact test was performed. For continuous variables, a t-test was used to compare two groups, with P < .05 considered statistically significant. For determination of positive predictors of rupture, a logistical regression analysis was used with the outcome variable being the presence of rupture, with each independent variable being evaluated as a univariate and multivariable predictor. A logistical regression analysis was also used to assess variables that may influence the occurrence of endoleaks for all patients. The outcome variable was the presence of any endoleaks after surgery had been performed. Finally, a Kaplan-Meier analysis, using a logrank test, compared freedom from explantation in those with and without endoleaks in r-EVAR and e-EVAR groups. Table I ) for infrarenal AAAs. In both groups, male patients dominated (e-EVAR, 76.6% men; r-EVAR, 70.5% men). Average age of the two groups was 73.6 years for both (range, 37-97 years for e-EVAR and 38-97 years for r-EVAR), whereas difference in aneurysm size was statistically significant between the two groups (average size in e-EVAR, 5.7 cm; average size for r-EVAR, 6.7 cm; P < .05). The types of endografts placed in the r-EVAR and e-EVAR groups are shown in Tables II and III, respectively. Estimated blood loss during the procedure was also collected; a mean of 394 mL for r-EVAR (range, 20-5000 mL) was significantly more than the mean of e-EVAR, which was 278 mL (range, 10-12,000 mL; P < .05). r-EVAR patients also displayed a significantly higher mortality rate than e-EVAR patients (n ¼ 39 [23.49%] vs n ¼ 26 [1.38%]; P < .01). The mortality by year during the period of study is shown in Table IV .
RESULTS

Between
Comorbidities. There was no significant difference in comorbidities between the two groups. The r-EVAR group had a slightly higher percentage of diabetic patients (n ¼ 27 for end-stage renal disease). The total incidence of colon ischemia including those patients who died was 14.4% (24 patients). Six patients (3.6%) required colonic resection with a 50% associated mortality (three patients).
Endoleaks. In comparing e-EVAR with r-EVAR, significant differences in endoleaks were noted between the two groups (Table V) . Compared with r-EVAR, e-EVAR patients had a significantly higher incidence of all endoleaks (n ¼ 538 [28.5%] vs n ¼ 27 [16.3%]; P < .001) as 
, and renal disease (n ¼ 3 [1.8%]). Abdominal compartment syndrome occurred in 30 (14%) patients undergoing r-EVAR. Ten of these patients died. All patients were treated with decompressive midline laparotomy.
Secondary interventions.
There was no significant difference in the total secondary interventions between the two groups (P ¼ .37 ; Table VII ). However, r-EVAR patients with endoleaks experienced a significantly higher incidence of stent graft explantation (r-EVAR, n ¼ 9 [5.42%]; e-EVAR, n ¼ 20 [1.06%]; P < .001; Table VIII) . When the groups were separated on the basis of occurrence of an endoleak, those without an endoleak had a higher stent explantation rate in the r-EVAR group (r-EVAR, n ¼ 5 [3.6%]; e-EVAR, n ¼ 11 [0.8%]; P ¼ .006). This trend of stent graft explantation also held true for those patients with an endoleak (r-EVAR, n ¼ 4 [14.8%]; e-EVAR, n ¼ 9 [1.67]; P < .001).
There were no significant differences in embolization procedures for treatment of endoleaks between the two groups (e-EVAR, n ¼ 216 [11.5%]; r-EVAR, n ¼ 11 [6 Kaplan-Meier analysis. A Kaplan-Meier analysis was done to compare freedom from both endoleaks and stent graft explantation over time. In looking at the e-EVAR group, there was no significant difference in explantation between those patients with an endoleak and those without (P ¼ .53, log-rank test ; Fig 1) , nor was there a difference in explantation in the r-EVAR group in comparing patients on the basis of incidence of an endoleak (P ¼ .19, log-rank test; Fig 2) . Freedom from endoleak between the e-EVAR and r-EVAR groups was also not significant (P ¼ .20, log-rank test; Fig 3) .
DISCUSSION
Advances in EVAR have come a long way since its first introduction more than two decades ago. Although we have learned much about the fate of endoleaks after e-EVAR, little is known about the incidence and behavior of endoleaks after r-EVAR. This study represents the largest single-center or multicenter experience reported to date that analyzes the fundamental outcome differences in elective and emergency EVAR and the impact of endoleaks in patients who undergo r-EVAR. Our findings of 166 r-EVAR and 1886 e-EVAR procedures indicate that r-EVAR patients have a significantly lower rate of all endoleaks (16.3% vs 28.5%) and more specifically a significantly lower incidence of type II endoleaks (9% vs 20.1%). This, however, is compounded by the fact that stents placed in r-EVAR have to be explanted more often than those placed in e-EVAR (5.42% vs 1.06%; P < .01). Stent graft explantation occurred in 14.8% (n ¼ 4/27) of r-EVAR patients who also had an endoleak, whereas only 1.67% (n ¼ 9/538) of e-EVAR patients with an endoleak required a stent graft explantation. Although the difference in coil embolization between the two groups also was not significant, there was a higher rate of the secondary intervention in the e-EVAR group. The lower rate of secondary interventions in the r-EVAR group may be due to poor follow-up of patients after discharge because of the referral nature of transported patients from remote areas. Therefore, the lower incidence of type II endoleaks may in part be secondary to a lack of surveillance. We focused our study on the outcomes of the patients who undergo e-EVAR vs r-EVAR and analyzed the behaviors exhibited by complications of such procedures. Overall, there was a much higher incidence of complications in the r-EVAR patients; complications that were significantly higher in the high-risk group include pulmonary complications, cardiac complications, colon ischemia, multisystem organ failure, cholecystitis, and abdominal compartment syndrome. The hemodynamic collapse secondary to aneurysm rupture and blood loss has long been known to have a negative impact on patient outcomes. This hemodynamic collapse, in light of a retroperitoneal hematoma, might also help explain lower type II endoleak incidence in r-EVAR patients compared with e-EVAR patients. Under routine circumstances, e-EVAR patients generally receive full anticoagulation during the procedure, whereas r-EVAR patients rarely are anticoagulated during the procedure; this too might have an impact on the rate of endoleaks as many of the lumbar arteries might be prone to thrombosis in nonanticoagulated patients after stent graft placement and aneurysm exclusion. The lower incidence of type II endoleaks seen in r-EVAR patients could be due to the fact that there has been massive trauma to the vasculature at the site of the aneurysm, which would release clotting factors from the injury in the body's attempt to repair the wound. Although there are a multitude of checks and balances set in place to keep these coagulation factors at the site of insult, with such a massive trauma to a major vessel, it would not be extreme to suggest that some of these clotting factors are entering adjacent vessels, such as the ones that would feed an aneurysm in a type II endoleak. This would have the same result as the theory described before that came to fruition from not giving anticoagulantsdbut with a different cause.
Finally, the other possible explanations for the discrepancy in endoleak incidence could be found in the patients themselves. This can be seen in the fact that there was a significantly higher mortality rate in r-EVAR patients than in e-EVAR patients (23.49% vs 1.38%; P < .01); therefore, it could be possible for these patients to have died before a potential type II endoleak could develop. Also, it has been described that the loss of STAT1 increases the risk of rupture in AAA patients 22 ; it can be hypothesized that either this genetic mutation alone or that of a similar type could be the cause of the low levels of a type II endoleak in patients because a type II endoleak has more to do with a patient's physiology than with the procedure itself (unlike that of type I, III, and IV endoleaks). Alternatively, the true incidence of type II endoleaks may be artifactually low in r-EVAR patients if that subset with abdominal compartment syndrome had ongoing bleeding from type II endoleaks leading to death. In addition, patients with other causes of death in this group might have had type II endoleaks that were not known. However, abdominal compartment syndrome may also be due to effects of overresuscitation and coagulopathy. 23, 24 Secondary outcomes are also an important measure of success when it comes to EVAR procedures. Whereas one study has reported on reinterventions in r-EVAR, 10 we wanted to look further in depth and compare those rates with e-EVAR. What we found was that the overall number of reinterventions was similar between the two groups. However, looking more closely, it was found that stent explantations were a major problem of r-EVAR, and thus undergoing this procedure puts a patient at a significantly greater risk than a patient undergoing e-EVAR. Coil embolization was by far the most prevalent reason for a secondary procedure and was done much more in e-EVAR patients, although this difference was not statistically significant (P ¼ .06). Overall, these results show slightly lower reintervention results for those undergoing r-EVAR (14.5%) compared with the 23% of r-EVAR patients previously described. 10 In addition to our findings of reinterventions and endoleaks varying between e-EVAR and r-EVAR, we also looked at possible predictors of both rupture and endoleaks. When the logistical analysis was run, the only result that was a positive predictor of rupture was the size of the aneurysm. Similarly, the only positive predictor value for an endoleak is for a patient to have elective surgery. Continuing with a multiple logistic regression after stepwise elimination of nonsignificant factors, it was found that both emergency procedures and smoking history reduce the risk of a possible endoleak. Likewise, doing the same for risk of rupture, aneurysm size was the only significant factor, whereas a comorbidity of renal disease had a P value of .078.
This study analyzed the largest number of ruptured EVAR patients to date, but several limitations could be improved on. The main weakness of this study is our restricted number of data points. The Vascular Registry database is the largest database of r-AAA patients, yet there were still only a total documented number of 166. Continuing to collect diligent data on these patients would allow more power from our results as well as enable us to conduct further testing between groups within the r-EVAR patients as opposed to comparing the group as a whole to either OSR or e-EVAR patient groups. Also, this was a retrospective review; a randomized controlled or case-control trial would be ideal. In addition, r-EVAR patients were selected from a group of r-AAA patients, and a choice was made to undergo EVAR as opposed to open repair, thus giving way to some selection bias. Last, there were several different types of endografts placed in both groups of patients. It is therefore possible that endoleaks and graft failure in general may have been due to a selection bias influenced by the surgeon's preference for the type of graft at operation.
CONCLUSIONS
The fate of endoleaks varies between e-EVAR and r-EVAR. The lower incidence of endoleaks in r-EVAR patients can mostly be explained by a lower incidence of overall type II endoleaks that could be secondary to hemodynamic instability, retroperitoneal hematoma, and avoidance of anticoagulation during these procedures. Although the incidence of type I endoleaks is comparable between e-EVAR and r-EVAR, the incidence of stent graft explantation during long-term follow-up is significantly higher for r-EVAR patients. This suggests vigilance in postoperative follow-up of r-EVAR patients. Whereas this study begins to characterize the procedure of r-EVAR, much more research must be done to fully understand the behavior of ruptured endovascular repair. Kaplan-Meier plot of freedom from endoleaks for both ruptured and nonruptured endovascular repair patients. e-EVAR, Elective endovascular aneurysm repair; r-EVAR, ruptured endovascular aneurysm repair.
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